Skip to content

the Effect of Niaoduqing Granules on Residual Renal Function and Volume Management in Peritoneal Dialysis Patients

the Effect of Niaoduqing Granules on Residual Renal Function and Volume Management in Peritoneal Dialysis Patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117299
Enrollment
Unknown
Registered
2026-01-22
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Dialysis

Interventions

Experimental Group: Niaoduqing Granules +peritoneal dialysis (PD)
Control Group:peritoneal dialysis (PD)

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18–70 years old, no gender limitation. 2. Indication: Undergoing peritoneal dialysis due to end-stage renal disease (ESRD). 3. Residual Renal Function: Baseline residual renal function = 2 ml/min/1.73 m² at the initiation of dialysis. 4. Informed Consent: Willing to participate in this study and has signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Having other severe primary diseases such as congestive heart failure, chronic obstructive pulmonary disease (COPD), myocardial infarction, liver cirrhosis, and active malignant tumors. 2. Poor patient compliance and inability to cooperate with the study. 3. Uncontrolled hypertension (systolic blood pressure [SBP] = 160 mmHg and/or diastolic blood pressure [DBP] = 100 mmHg); symptomatic hypotension or systolic blood pressure < 90 mmHg at screening. 4. Inability to receive peritoneal dialysis due to various reasons such as abdominal surgery and intestinal adhesion. 5. A history of kidney transplantation or maintenance hemodialysis. 6. Pregnant or lactating women, or subjects allergic to the study drug. 7. Complicated with mental illness or unable to complete follow-up. 8. Participation in other clinical trials of drugs or medical devices within 3 months.

Design outcomes

Primary

MeasureTime frame
KT/V;

Secondary

MeasureTime frame
Rate of decline in residual renal function;Capacity load indicators: time to anuria, extracellular water (ECW) changes;

Countries

China

Contacts

Public ContactYin Yao

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog

1900343963@qq.com+86 137 2037 9867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026